Porcine cancer models for translational oncology

Large-animal cancer models are needed to advance the development of innovative and clinically applicable tumor diagnostic, therapeutic, and monitoring technologies. We developed a genetically modified porcine model of cancer based on a TP53 mutation, and established its utility for tracking tumorigenesis in vivo through non-invasive clinical imaging approaches.

[1]  D. Meyerholz,et al.  Development and translational imaging of a TP53 porcine tumorigenesis model. , 2014, The Journal of clinical investigation.

[2]  J. Fraumeni,et al.  Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  David K. Meyerholz,et al.  Disruption of the CFTR Gene Produces a Model of Cystic Fibrosis in Newborn Pigs , 2008, Science.

[4]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[5]  M. Tempero,et al.  Therapeutic advances in pancreatic cancer. , 2013, Gastroenterology.

[6]  Johan Bussink,et al.  PET–CT for radiotherapy treatment planning and response monitoring in solid tumors , 2011, Nature Reviews Clinical Oncology.

[7]  F. Alt,et al.  Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. , 2008, Genes & development.

[8]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[9]  A. Børresen-Dale,et al.  TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.

[10]  Hao Yin,et al.  CRISPR-mediated direct mutation of cancer genes in the mouse liver , 2014, Nature.